C-HQSV

FILE C-HQSV·COMPANY·CURATED BY ETERNAL SEARCH

GEn1E Lifesciences

dual signal modulators, kinase modulation, AI drug discovery

modulatingsmall molecule

gen1e.com·San Francisco, California, United States·Seed

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-HQSV

Projects

GEn-1124 Oral

phase 1

drug program · high · Wed Oct 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Assess oral GEn-1124 pharmacokinetics and safety in healthy subjects as an oral formulation of the company's p38/MK2 dual signal modulator program.

Single oral dose clinical pharmacokinetic and safety study in healthy volunteers, including in-clinic monitoring and follow-up calls after dosing.

Clinical trial to determine pharmacokinetics and safety after single oral dosing in healthy subjects.

GEn-1124 IV

phase 2

drug program · high · Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Evaluate GEn-1124 as a precision therapy for acute respiratory distress syndrome by modulating inflammatory p38/MK2 signaling and stabilizing endothelial barrier function.

Intravenous small-molecule dual signal modulator of p38 alpha/MK2 signaling; Phase 2 ARDS study using early IV infusion dosing after ARDS diagnosis, followed by a second dose about 8 hours later and twice-daily dosing for 5 days.

Two-part Phase 2 study in subjects with ARDS to evaluate safety and tolerability.

Published preclinical data report improved p38 alpha binding affinity, aqueous solubility, endothelial barrier-stabilizing activity, lung protection in vivo, and survival improvements in mouse acute lung injury and influenza pneumonia models.

GEn-1123 Oral

undisclosed

drug program · medium

Develop an oral program listed in GEn1E's pipeline for inflammatory or rare disease applications within its kinase-modulation portfolio.

Oral drug program; specific target, indication, and trial method were not disclosed in the supplied material.

Listed on the company pipeline as GEn-1123 Oral.

GRID AI Platform

exploratory

platform · medium

Accelerate drug discovery and development by connecting curated public and proprietary data across genes, pathways, proteins, diseases, and compounds.

AI drug discovery platform integrating curated public and proprietary biomedical data to support target, pathway, disease, and compound analysis.

Described by the company as its AI platform supporting drug development.

NextGen ERK 1/2 Modulators

undisclosed

drug program · medium

Develop next-generation modulators of ERK 1/2 signaling as part of GEn1E's precision therapy pipeline for inflammatory and rare diseases.

ERK 1/2 modulation program; supplied material does not disclose compound names, indication, or trial design.

Listed on the company pipeline as NextGen ERK 1/2 Modulators.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Projects

GEn-1124 Oral

phase 1

drug program · high · Wed Oct 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Assess oral GEn-1124 pharmacokinetics and safety in healthy subjects as an oral formulation of the company's p38/MK2 dual signal modulator program.

Single oral dose clinical pharmacokinetic and safety study in healthy volunteers, including in-clinic monitoring and follow-up calls after dosing.

Clinical trial to determine pharmacokinetics and safety after single oral dosing in healthy subjects.

GEn-1124 IV

phase 2

drug program · high · Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Evaluate GEn-1124 as a precision therapy for acute respiratory distress syndrome by modulating inflammatory p38/MK2 signaling and stabilizing endothelial barrier function.

Two-part Phase 2 study in subjects with ARDS to evaluate safety and tolerability.

GEn-1123 Oral

undisclosed

drug program · medium

Develop an oral program listed in GEn1E's pipeline for inflammatory or rare disease applications within its kinase-modulation portfolio.

Oral drug program; specific target, indication, and trial method were not disclosed in the supplied material.

Listed on the company pipeline as GEn-1123 Oral.

GRID AI Platform

exploratory

platform · medium

Accelerate drug discovery and development by connecting curated public and proprietary data across genes, pathways, proteins, diseases, and compounds.

AI drug discovery platform integrating curated public and proprietary biomedical data to support target, pathway, disease, and compound analysis.

Described by the company as its AI platform supporting drug development.

NextGen ERK 1/2 Modulators

undisclosed

drug program · medium

Develop next-generation modulators of ERK 1/2 signaling as part of GEn1E's precision therapy pipeline for inflammatory and rare diseases.

ERK 1/2 modulation program; supplied material does not disclose compound names, indication, or trial design.

Listed on the company pipeline as NextGen ERK 1/2 Modulators.